BRPI0917205A2 - vacina polivalente - Google Patents

vacina polivalente

Info

Publication number
BRPI0917205A2
BRPI0917205A2 BRPI0917205A BRPI0917205A BRPI0917205A2 BR PI0917205 A2 BRPI0917205 A2 BR PI0917205A2 BR PI0917205 A BRPI0917205 A BR PI0917205A BR PI0917205 A BRPI0917205 A BR PI0917205A BR PI0917205 A2 BRPI0917205 A2 BR PI0917205A2
Authority
BR
Brazil
Prior art keywords
multipurpose
vaccine
multipurpose vaccine
Prior art date
Application number
BRPI0917205A
Other languages
English (en)
Portuguese (pt)
Inventor
Barton F Haynes
Beatrice H Hahn
Bette T Korber
Hua-Xin Liao
Norman Letvin
William Fischer
Original Assignee
Beth Israel Hospital
Univ Duke
Los Alamos Nat Security Llc
Univ Alabama Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Univ Duke, Los Alamos Nat Security Llc, Univ Alabama Res Found filed Critical Beth Israel Hospital
Publication of BRPI0917205A2 publication Critical patent/BRPI0917205A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0917205A 2008-08-14 2009-08-14 vacina polivalente BRPI0917205A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/192,015 US7951377B2 (en) 2005-08-23 2008-08-14 Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
PCT/US2009/004664 WO2010019262A2 (en) 2008-08-14 2009-08-14 Polyvalent vaccine

Publications (1)

Publication Number Publication Date
BRPI0917205A2 true BRPI0917205A2 (pt) 2015-11-10

Family

ID=41669535

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917205A BRPI0917205A2 (pt) 2008-08-14 2009-08-14 vacina polivalente

Country Status (9)

Country Link
US (6) US7951377B2 (enExample)
EP (2) EP2318430A4 (enExample)
JP (2) JP2011530309A (enExample)
CN (1) CN102177175A (enExample)
AU (1) AU2009282442B2 (enExample)
BR (1) BRPI0917205A2 (enExample)
CA (1) CA2733898C (enExample)
IL (1) IL211184B (enExample)
WO (1) WO2010019262A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
AU2006283101B2 (en) * 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine
NZ593598A (en) 2008-11-18 2013-02-22 Beth Israel Hospital Optimized antiviral vaccines with improved cellular immunogenicity
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
KR20150095704A (ko) 2012-12-13 2015-08-21 베일러 리서치 인스티튜트 글루코스 수송체 1 결핍증의 치료를 위한 트라이헵타노인
US10010606B2 (en) * 2013-09-30 2018-07-03 Los Alamos National Security, Llc Mosaic conserved region HIV immunogenic polypeptides
JP6769869B2 (ja) * 2013-10-16 2020-10-14 ニユー・イングランド・バイオレイブス・インコーポレイテツド 強化された特性を有する逆転写酵素
WO2015143193A1 (en) * 2014-03-19 2015-09-24 Duke University Swarm immunization with envelopes from ch505
EP3122881A4 (en) * 2014-03-25 2017-11-15 Duke University Mosaic hiv-1 sequences and uses thereof
US10322141B2 (en) 2014-03-31 2019-06-18 Duke University Compositions comprising CH848 envelopes and uses thereof
US10232034B2 (en) 2014-09-28 2019-03-19 Duke University Compositions comprising CH505 envelopes, and trimers
US10968255B2 (en) 2016-03-01 2021-04-06 Duke University Compositions comprising HIV envelopes to induce CH235 lineage antibodies
WO2017152146A2 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
WO2018067580A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
US11230572B2 (en) 2016-10-17 2022-01-25 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
WO2018218225A1 (en) 2017-05-25 2018-11-29 Duke University Compositions comprising modified hiv envelopes
EP3860650A4 (en) 2018-10-01 2022-06-29 Duke University Hiv-1 envelope stabilizing mutations
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021081437A2 (en) 2019-10-23 2021-04-29 Duke University Compositions comprising v2 opt hiv envelopes
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6503753B1 (en) 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
US20040115621A1 (en) 2000-02-18 2004-06-17 Allen Rodrigo Ancestral viruses and vaccines
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2002363436A1 (en) 2001-11-07 2003-05-19 Duke University Polyvalent immunogen of hiv
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
US7425611B2 (en) 2003-03-28 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use
AU2004279362B2 (en) 2003-09-15 2011-03-17 Genvec, Inc. HIV vaccines based on ENV of multiple clades of HIV
BRPI0414443A (pt) 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
WO2005035555A1 (en) * 2003-10-10 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies
AU2006283101B2 (en) 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
CA2626257A1 (en) 2005-10-17 2007-04-26 Novartis Ag Multiclade hiv vaccines
WO2012047267A2 (en) 2010-09-28 2012-04-12 Duke University Polyvalent immunogen

Also Published As

Publication number Publication date
IL211184B (en) 2019-02-28
US9044445B2 (en) 2015-06-02
WO2010019262A2 (en) 2010-02-18
CA2733898A1 (en) 2010-02-18
US9844590B2 (en) 2017-12-19
EP3178842A1 (en) 2017-06-14
US20150265700A1 (en) 2015-09-24
US7951377B2 (en) 2011-05-31
US9011873B2 (en) 2015-04-21
CN102177175A (zh) 2011-09-07
US20160067329A1 (en) 2016-03-10
AU2009282442B2 (en) 2015-06-04
US20120121631A1 (en) 2012-05-17
US9821053B2 (en) 2017-11-21
EP2318430A2 (en) 2011-05-11
JP2014207910A (ja) 2014-11-06
EP3178842B1 (en) 2020-10-07
US20090198042A1 (en) 2009-08-06
EP2318430A4 (en) 2012-08-29
US20180185471A1 (en) 2018-07-05
IL211184A0 (en) 2011-04-28
WO2010019262A3 (en) 2010-05-27
AU2009282442A1 (en) 2010-02-18
JP2011530309A (ja) 2011-12-22
CA2733898C (en) 2017-06-20
US20110301328A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
DK2114993T3 (da) Vaccine
HRP20181347T1 (hr) Formulacije dvoslojne tablete
DK2200646T3 (da) RNA-Vacciner
PT2813570T (pt) Resumo
ATE450271T1 (de) Impfstoff
EP2501439A4 (en) FAN
BRPI0907376A2 (pt) Fotobiorretador
PT3045471T (pt) Resumo
BRPI0909770A2 (pt) Vacina, e, kit
FIC20240018I1 (fi) Vamoroloni
BRPI0914649A2 (pt) Piprazolo-quinazolinas
IL211184A0 (en) Polyvalent vaccine
DK2837348T3 (da) Kryokirurgiske fremgangsmåder
BRPI0907522A2 (pt) biarlamidas
BRPI0915562A2 (pt) tamis melhorado
BRPI0915442A2 (pt) tamis melhorado
PL2315653T3 (pl) Uchwyt
BRPI0909634A2 (pt) 2-aminoquinolinas
HUE054030T2 (hu) Fejlesztett formulációk
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0909637A2 (pt) 2-aminoquinolinas
BRPI0921578A2 (pt) vacinas unitemporais
AT507449A3 (de) Dämmstoffbefestiger
DK2254963T3 (da) Kerne-skal-flowforbedrer
HUE053202T2 (hu) Gyors hatóanyag-leadású készítmények

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]